Xtant Medical Stock Price, News & Analysis

Xtant Medical (NYSE American: XTNT) will release its third-quarter 2025 financial results for the period ended September 30, 2025 before market open on Tuesday, November 11, 2025. Sean Browne, President and CEO, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET the same day.

Conference dial-in details: 888-506-0062 (U.S.), international 973-528-0011, passcode 579614. A live webcast will be available at https://www.webcaster5.com/Webcast/Page/3039/52972, and a replay will be posted under Investor Info at https://xtantmedical.com/.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

CEO Sean Browne and CFO Scott Neils will represent the company at the conference, which takes place September 8-10, 2025, in New York and virtually. The company's presentation will be available on-demand starting September 5 at 7:00 A.M. ET. Management will also conduct virtual one-on-one meetings with investors on September 8th.

Xtant Medical (NYSE American: XTNT) reported strong Q2 2025 financial results with revenue growing 18% to $35.4 million. The company achieved significant improvements, including a gross margin of 68.6% and net income of $3.6 million, compared to a net loss in the prior year.

Key developments include the planned sale of non-core assets to Companion Spine for $19.2 million and the launch of two new products: OsteoFactor Pro™ and Trivium™. The company has raised its FY25 revenue guidance to $131-135 million, projecting 11-15% growth. Operating performance showed marked improvement with Adjusted EBITDA of $6.9 million and positive operating cash flow of $1.2 million.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has announced its participation in the upcoming CG 45th Annual Growth Conference.

CEO Sean Browne and CFO Scott Neils will represent the company at the event, which is scheduled for August 12, 2025, at 3:30 PM ET in Boston, MA. The format will include both one-on-one meetings and a presentation. Interested parties can access the webcast through the provided link.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before market open.

The company will host a conference call at 8:30 AM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call through domestic (877-545-0523) and international (973-528-0016) dial-in numbers using passcode 482755. A webcast will be available, with a replay accessible on the company's website after the live call.

Companion Spine LLC has announced a definitive agreement to acquire Paradigm Spine GmbH and its spine implant portfolio from Xtant Medical Holdings (NYSE:XTNT). The acquisition includes the Coflex® and CoFix® spine implants, which have been used to treat over 390,000 patients globally.

The strategic acquisition positions Companion Spine as the world's largest provider of minimally invasive posterior dynamic spine stabilization solutions. The combined portfolio will offer comprehensive treatment options for lumbar spinal stenosis (LSS) and degenerative disc disease (DDD), with products distributed in more than 60 countries.

The transaction is expected to close in Q3 2025, subject to closing conditions. For Xtant Medical, the sale will allow focus on core business while reducing debt and improving their balance sheet.

Xtant Medical (NYSE American: XTNT) has announced agreements to sell its Coflex® and CoFix® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC for $19.2 million. The transaction includes $11 million in cash at closing and $8.2 million in short-term seller financing.

The deal includes a $2.5 million non-refundable cash deposit, with potential for two additional $2.5 million deposits if Companion Spine needs extra time for financing. The transaction is expected to close in Q3 2025, with the promissory note maturing on December 31, 2025.

This strategic divestment will allow Xtant to focus on its core orthobiologics business while improving its balance sheet. Select Xtant commercial team members will transition to Companion Spine to support the products.

Xtant Medical Holdings (NYSE: XTNT) has launched OsteoFactor Pro™, an innovative allogeneic growth factor solution designed to enhance bone healing in orthopedic and spine procedures. The product features a biphasic release profile that promotes bone regeneration through targeted angiogenesis, chemotaxis, and osteogenesis.

This ready-to-use solution is compatible with synthetic, allograft, or autograft scaffolds, offering surgeons versatility in bone regeneration approaches. With this launch, Xtant becomes the first vertically integrated company to provide solutions across all five major orthobiologic categories, including demineralized bone matrix, cellular allografts, synthetics, structural allografts, and growth factors.

Xtant Medical (NYSE American: XTNT) reported strong Q1 2025 financial results with revenue increasing 18% year-over-year to $32.9 million. The company achieved positive net income of $58,000, compared to a net loss of $4.4 million in Q1 2024. Key highlights include gross margin of 61.5%, Adjusted EBITDA of $3.0 million, and positive operating cash flow of $1.3 million. The growth was primarily driven by increased orthobiologics sales and licensing revenue. Xtant recently launched Trivium™, a next-generation demineralized bone matrix allograft, and completed a secondary private sale of shares by OrbiMed Advisors. Based on strong performance, the company increased its 2025 revenue guidance to $127-131 million, representing 8-12% growth.